Posts tagged GMP Securities
Shawn Aspden joins Bloom Burton as managing director

Shawn Aspden, a 20-year veteran of the Canadian capital markets, has joined Bloom Burton & Co. as managing director. Mr. Aspden recently served was vice chairman and head of North American institutional equity sales at GMP Securities.

In the role of managing director, Mr. Aspden will expand Bloom Burton’s ability to serve Canadian institutional investors as they consider the important pharmaceutical, biotechnology and healthcare sectors. He will broaden the awareness and distribution of Bloom Burton’s investment banking and advisory capabilities, award-winning equity research, and events such as the firm’s flagship Bloom Burton Healthcare Investor Conference.

Read More
GMP starts Profound Medical at speculative buy

GMP Securities has initiated coverage of Profound Medical (TSX-V:PRN) with a “speculative buy” rating and price target of $2. The stock closed at $1.50 on Monday.

The company is focused on developing and commercializing an innovative therapy for the ablation of prostate cancer tissue, using real-time MRI to greatly improve accuracy, while reducing side effects.

Read More